Phapros Tbk PT Total Liabilities
Phapros Tbk PT total liabilities. Based on the latest financial reports, Phapros Tbk PT (PEHA) has total liabilities worth Rp1.01 Trillion IDR (≈ $59.39 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PEHA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Phapros Tbk PT (2011–2025)
Total liabilities of Phapros Tbk PT from 2011 to 2025. This chart illustrates how Phapros Tbk PT's total liabilities have evolved over time, based on quarterly financial data. Explore PEHA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Phapros Tbk PT Competitors by Total Liabilities
The table below lists competitors of Phapros Tbk PT ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
Greece | €18.91 Million |
|
Imexhs Ltd
AU:IME
|
Australia | AU$8.36 Million |
|
Daesang Corp Preference Shares
KO:001685
|
Korea | ₩2.60 Trillion |
|
Mico BioMed Co. Ltd.
KQ:214610
|
Korea | ₩7.88 Billion |
|
Destinasi Tirta Nusantara Tbk
JK:PDES
|
Indonesia | Rp216.64 Billion |
|
Wintao Communications Co. Ltd
SHE:301139
|
China | CN¥1.42 Billion |
|
Bass Oil Ltd
AU:BAS
|
Australia | AU$6.36 Million |
|
Bd Multimedia
PA:ALBDM
|
France | €2.94 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Phapros Tbk PT's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Phapros Tbk PT assets under control.
Liquidity & Leverage Metrics
Phapros Tbk PT Total Liabilities Ratios Explained
Phapros Tbk PT total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Phapros Tbk PT's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Phapros Tbk PT (2011–2025)
The table below shows the annual total liabilities of Phapros Tbk PT from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Rp959.70 Billion ≈ $56.23 Million |
-7.45% |
| 2024-12-31 | Rp1.04 Trillion ≈ $60.76 Million |
+4.15% |
| 2023-12-31 | Rp995.56 Billion ≈ $58.34 Million |
-3.76% |
| 2022-12-31 | Rp1.03 Trillion ≈ $60.62 Million |
-5.75% |
| 2021-12-31 | Rp1.10 Trillion ≈ $64.31 Million |
-6.60% |
| 2020-12-31 | Rp1.18 Trillion ≈ $68.86 Million |
-7.84% |
| 2019-12-31 | Rp1.28 Trillion ≈ $74.72 Million |
+18.19% |
| 2018-12-31 | Rp1.08 Trillion ≈ $63.22 Million |
+127.35% |
| 2017-12-31 | Rp474.55 Billion ≈ $27.81 Million |
+81.67% |
| 2016-12-31 | Rp261.21 Billion ≈ $15.31 Million |
+13.11% |
| 2015-12-31 | Rp230.93 Billion ≈ $13.53 Million |
+0.48% |
| 2014-12-31 | Rp229.84 Billion ≈ $13.47 Million |
-8.68% |
| 2013-12-31 | Rp251.69 Billion ≈ $14.75 Million |
+37.52% |
| 2012-12-31 | Rp183.02 Billion ≈ $10.72 Million |
+48.29% |
| 2011-12-31 | Rp123.42 Billion ≈ $7.23 Million |
-- |
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more